Anbio Biotechnology (NASDAQ:NNNN – Get Free Report) shares saw strong trading volume on Monday . 199,090 shares were traded during trading, an increase of 223% from the previous session’s volume of 61,549 shares.The stock last traded at $25.46 and had previously closed at $21.91.
Wall Street Analyst Weigh In
Separately, Weiss Ratings initiated coverage on shares of Anbio Biotechnology in a report on Monday, January 26th. They issued a “sell (d+)” rating for the company. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.
Read Our Latest Report on Anbio Biotechnology
Anbio Biotechnology Trading Down 15.4%
Anbio Biotechnology Company Profile
Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.
See Also
- Five stocks we like better than Anbio Biotechnology
- [No Brainer Gold Play]: “Show me a better investment.”
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- The gold chart Wall Street is terrified of…
- NEW LAW: Congress Approves Setup For Digital Dollar?
- When to buy gold (mathematically)
Receive News & Ratings for Anbio Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anbio Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
